Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21292103 | 0.87 | HSD17B10 (0.34) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL21292107 | 0.78 | ALDH1A1 (0.36) | HSD17B10LMNAALDH1A1KDM4CTSHR | |
| SCHEMBL2376039 | 0.75 | HSD17B10 (0.39) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL17536132 | 0.74 | HSD17B10 (0.38) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL21292112 | 0.72 | HSD17B10 (0.37) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL642543 | 0.69 | TSHR (0.40) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL8614546 | 0.68 | ALDH1A1 (0.44) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL17536124 | 0.68 | TSHR (0.39) | HSD17B10LMNAALDH1A1KDM4CTSHR | |
| SCHEMBL7080606 | 0.67 | HSD17B10 (0.36) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL17294176 | 0.67 | ALDH1A1 (0.43) | HSD17B10LMNAALDH1A1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345767-A1 | METHODS AND DEVICES FOR GENERATING CORE-SHELL DROPLETS AND PARTICLES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-11-13 | — | — | US | disclosed |
| CN-108743549-B | Self-regulating release of active pharmaceutical ingredient | 阿库拉制药公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240108726-A1 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT | ACURA PHARMACEUTICALS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11857629-B2 | Methods and compositions for self-regulated release of active pharmaceutical ingredient | ACURA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023239688-A1 | METHODS AND DEVICES FOR GENERATING CORE-SHELL DROPLETS AND PARTICLES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230330044-A1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS INC (US) | 2023-10-19 | — | — | US | disclosed |
| US-11723885-B2 | Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse | ACURA PHARMACEUTICALS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| CN-116367864-A | Controlled release filler composition and capsule containing the same | R·P·谢勒技术有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116322655-A | Soft gel capsule for regulating release | R·P·谢勒技术有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230158008-A1 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENTS | ACURA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20120202839-A1 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS | ACURA PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-1993519-A2 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS | ACURA PHARMACEUTICALS, INC. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080152595-A1 | Methods and compositions for deterring abuse of orally administered pharmaceutical products | ACURA PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20070231268-A1 | Methods and compositions for deterring abuse of orally administered pharmaceutical products | ACURA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007106550-A2 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS | ACURA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1817011-A2 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS | ACURA PHARMACEUTICALS, INC. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060177380-A1 | Methods and compositions for deterring abuse of orally administered pharmaceutical products | ACURA PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006058249-A9 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS | ACURA PHARMACEUTICALS INC (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006058249-A2 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS | ACURA PHARMACEUTICALS, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060110327-A1 | Methods and compositions for deterring abuse of orally administered pharmaceutical products | ACURA PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |